GLP-1 Shift Drives Weight Watchers to Q4 Loss, 12% Revenue Decline
WW sits 97% above its 52-week low of $10.915.
Summary
WW International reported a significant fourth-quarter loss of $5.83 million, or 58 cents per share, a stark reversal from a profit in the prior year. Revenue also declined by 12% to $162.8 million. This performance is primarily attributed to the ongoing shift of consumers towards GLP-1 medications, which is profoundly disrupting demand for the company's traditional weight-loss programs. While the company recently filed an 8-K broadly covering Q4 results and provided 2026 guidance, this headline provides the critical negative details of the quarterly performance. The results underscore the severe operational challenges WW faces as it attempts to pivot its strategy to integrate GLP-1 access with behavioral support. Investors will closely watch the growth of its clinical subscription business as a key indicator of its ability to adapt to this industry transformation.
At the time of this announcement, WW was trading at $21.50 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $210.5M. The 52-week trading range was $10.92 to $105.24. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.